Primary outcome measure
Allergic
Improvement of symptoms and reduced use of standard of care medication in patients treated with methylprednisolone compared to placebo. The daily symptoms and medications used during the study period were registered according to European Academy of Allergic and Clinical Immunologys (EAACI:s) recommended scoring system A daily symptom score(dSS), daily medication score (dMS) and daily combined symptom- and medication score) dCSMS were expressed as the median value of each group every day of the study period. The median value was used because of the limited sample size. Minimal clinical important difference (MCID) has not been defined for combined symptom- and medication score. We estimated a significant MCID to about 20% 